Table 1.
Baseline characteristics of patients in the study, with and without progression, defined as requirement for radical therapy
| All | No progression | Progression | Odds ratio | P | |
|---|---|---|---|---|---|
| Number of men, n (%) | 211 | 153 (72.5) | 58 (27.5) | – | – |
| Mean age, year | 65.3 (64.5,66.1) | 65.1 (64.2, 66.1) | 65.6 (64.0, 67.2) | – | 0.55 |
| Median number of positive cores | 1 (1–2.25) | 1 (1–2) | 2 (1–4) | – | 0.001 |
| More than two positive cores | 50 (23.7) | 25 (16.3) | 25 (43.1) | 3.88 (1.98–7.60) | <0.001 |
| Median percentage length cores involved | 5 (2.5–10) | 5 (2.5–10) | 5 (2.5–15) | – | 0.05 |
| Mean PSA | 6.8 (6.2, 7.3) | 6.9 (6.1, 7.6) | 6.5 (5.7, 7.2) | – | 0.89 |
| Median PSA density | 0.11 (0.08–0.17) | 0.10 (0.08–0.16) | 0.12 (0.10, 0.18) | – | 0.03 |
| Visible lesion on first MRI, n (%) | 125 (59.2) | 78 (51.0) | 47 (81.0) | 4.1 (2.0–8.5) | <0.001 |
| Had confirmatory biopsy, n (%) | 151 (71.6) | 105 (68.6) | 46 (79.3) | 1.8 (0.9–3.6) | 0.13 |
Values are mean (95% CI) or (median 25th, 75th) unless otherwise specified. Reasons for radical therapy are described in the text.